GET DAILY SIGNALSPepGen (PEPG) Q3 Results Show Modest Loss Miss and Extended Cash Runway with New Trial Data
Key Takeaways
- PepGen reported a net loss of $19.4 million, or $0.28 per share, for the third quarter ended September 30, 2026.
- The per-share loss came in slightly wider than the consensus estimate of a $0.27 loss.
- Alongside results, PepGen disclosed positive topline data from the 10 mg/kg cohort of its FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
- Cash, cash equivalents, and marketable securities totaled $104.8 million, which management expects to fund operations into 2028.
- Research and development (R&D) expenses rose to $14.5 million from $13.4 million a year earlier, while general and administrative (G&A) expenses increased to $5.9 million.
- The U.S. FDA selected PGN-EDODM1 for its CMC Development and Readiness Pilot program, aimed at de-risking manufacturing development.
Why the Quarter Matters for This Pre-Revenue Biotech
As a clinical-stage biotechnology company, PepGen generates no product revenue, so its quarterly earnings release functions less as a measure of sales and more as a checkpoint on cash discipline, spending trajectory, and clinical execution. Investors focus primarily on the progress of PGN-EDODM1, the company's lead candidate for myotonic dystrophy type 1 (DM1), a rare, progressive neuromuscular disease with no approved disease-modifying therapies. This quarter carried extra weight because results arrived alongside the long-awaited topline readout from the 10 mg/kg cohort of the FREEDOM2-DM1 trial, a milestone management had flagged earlier in the year. Combined, the financials and the data update give the market a clearer view of both PepGen's balance-sheet runway and the clinical signal supporting its lead program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Numbers Behind the Report
For the third quarter of 2026, PepGen posted a net loss of $19.4 million, or $0.28 basic and diluted net loss per share, compared with a net loss of $18.0 million, or $0.52 per share, in the same period a year earlier. The result narrowly missed the consensus estimate of a $0.27 per-share loss. As expected for a pre-revenue company, PepGen recorded no product sales.
R&D expenses were $14.5 million, up from $13.4 million a year ago, reflecting advancing clinical activity. G&A expenses rose to $5.9 million from $5.2 million. The company ended the quarter with $104.8 million in cash, cash equivalents, and marketable securities and approximately 69.3 million shares outstanding. Management said the current cash position is expected to fund operations into 2028, an extension from the prior "into 2H 2027" guidance. From what I see, the extended runway is a meaningful improvement for planning purposes.
How the Market Viewed the Update
Sentiment around PepGen's third-quarter report was shaped less by the modest earnings miss than by the simultaneous clinical data release. Because PepGen is pre-revenue, a one-cent difference in the per-share loss typically matters less to investors than the direction of the lead program. The positive topline results from the 10 mg/kg cohort of FREEDOM2-DM1 gave investors a tangible data point on PGN-EDODM1's safety and activity at a higher dose, while the extended cash runway into 2028 reduced near-term financing overhang. Still, the trial remains subject to a partial clinical hold in the United States, which continues to be a key risk factor that investors are monitoring alongside the progression toward higher-dose cohorts and future regulatory engagement.
What to Watch in the Months Ahead
Looking ahead, the central catalyst for PepGen remains the FREEDOM2-DM1 program. Results from the highest-dose 12.5 mg/kg cohort are expected in the first half of 2027, and the company has said it plans to engage with regulators in an end-of-Phase 2 meeting to discuss a potential registrational program pending results from the 10 and 12.5 mg/kg cohorts.
Regulatory progress will also be important. The partial clinical hold imposed by the U.S. FDA remains in place, and how quickly PepGen resolves the agency's preclinical questions could influence U.S. trial timelines even though enrollment outside the U.S. has continued.
On the financial side, investors will watch whether the company's stated runway into 2028 holds as trial activity expands, and whether R&D spending continues to climb as later-stage cohorts and open-label extension work advance. The FDA's selection of PGN-EDODM1 for the CMC Development and Readiness Pilot program may also shape manufacturing-readiness planning ahead of any Phase 3 program. Taken together, data readouts, regulatory milestones, and cash management will likely drive the stock's narrative over the coming quarters. I’m watching this closely as more data comes in.
Using AI Tools for Biotech Research
In my own process, I turned to Tickeron’s AI Screener to quickly scan for comparable clinical-stage names and assess relative technical setups. The tool lets users filter by fundamentals, volatility, and AI signals, which can surface ideas faster than manual reviews when following names like PepGen. It has become a regular part of how I cross-check sector context before digging deeper into trial timelines or balance-sheet details.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PEPG's RSI Indicator reaches into overbought territory
The RSI Indicator for PEPG moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PEPG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PEPG broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 59 cases where PEPG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on PEPG as a result. In 77 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for PEPG just turned positive on November 10, 2026. Looking at past instances where PEPG's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
PEPG moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PEPG advanced for three days, in 198 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 102 of 112 cases where PEPG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.431) is normal, around the industry mean (3.498). P/E Ratio (-2.470) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. PEPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement